Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of MDX2003 in relapsed or refractory B-cell malignancies
2026-526661-26-00Phase 2Authorised
- Sponsor
- ModeX Therapeutics
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of MDX2003 in B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 8 more (2 arms), sponsored by ModeX Therapeutics. Primary endpoints: Safety and tolerability in Part A, Pharmacokinetic and pharmacodynamic assessments in Part A and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
MDX2003
03
Conditions
B-cell malignancydiffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2026-526661-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526661-26-00.